​

Beam Therapeutics Ownership | Who Owns Beam Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Beam Therapeutics Ownership Summary

Beam Therapeutics is owned by 25.87% institutional investors, 1.36% insiders, and 72.76% retail investors. Ark investment management is the largest institutional shareholder, holding 12.27% of BEAM shares. ARK Disruptive Innovation Full Composite is the top mutual fund, with 6.12% of its assets in Beam Therapeutics shares.

BEAM Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockBeam Therapeutics25.87%1.36%72.76%
SectorHealthcare Stocks 35.56%12.08%52.36%
IndustryBiotech Stocks 35.43%12.01%52.56%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ark investment management12.13M12.27%$289.14M
Fmr12.61M12.21%$432.74M
Farallon capital management10.13M10.25%$241.51M
Blackrock7.63M9.34%$178.87M
Vanguard group9.19M8.96%$254.84M
Blackrock funding, inc. /de9.00M8.71%$308.80M
State street5.83M5.64%$199.99M
Arch venture management4.54M4.59%$108.19M
Vanguard capital management4.60M4.45%$157.85M
Kynam capital management, lp3.68M3.72%$87.75M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Mwg management2.27M67.66%$55.02M
Arch venture management4.54M15.98%$108.19M
Kynam capital management, lp3.68M5.41%$87.75M
Contrarius group1.61M2.55%$55.41M
Casdin capital1.35M2.44%$32.17M
Ark investment management12.13M2.25%$289.14M
Redmile group1.24M1.95%$29.49M
Nikko asset management americas3.46M1.53%$118.54M
Farallon capital management10.13M1.38%$241.51M
Peregrine investment management70.00K1.02%$2.40M

Top Buyers

HolderShares% AssetsChange
Morgan stanley1.95M0.00%1.30M
Kynam capital management, lp3.68M5.41%1.24M
Contrarius group1.61M2.55%1.08M
Blackrock7.63M0.00%928.75K
Deep track capital, lp820.76K0.32%820.76K

Top Sellers

HolderShares% AssetsChange
Darwin global management---2.12M
Temasek (private)---1.81M
Woodline partners lp---993.07K
Deerfield management company, l.p. (series c)---877.81K
Logos global management lp---500.00K

New Positions

HolderShares% AssetsChangeValue
Deep track capital, lp820.76K0.32%820.76K$19.56M
Arrowstreet capital, limited partnership296.29K0.00%296.29K$10.17M
Mackenzie financial185.50K0.01%185.50K$6.37M
Adage capital partners gp175.00K0.01%175.00K$4.25M
Edgestream partners96.65K0.10%96.65K$3.32M

Sold Out

HolderChange
Lloyd advisory services, llc.-1.00
Vermillion wealth management-1.00
Curio wealth-2.00
Global financial private client-4.00
Twin peaks wealth advisors-4.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 2026120-53.13%25,591,358-76.05%250.24%66-51.82%28-58.21%
Dec 31, 202575-67.39%17,407,248-83.67%160.16%41-67.20%20-61.54%
Sep 30, 202580-63.96%18,739,586-81.85%180.18%38-66.37%19-70.31%
Jun 30, 2025229-4.98%108,356,4618.36%1060.82%117-17.61%6544.44%
Mar 31, 20252421.26%101,365,37024.41%1151.18%14316.26%46-28.13%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
ARK Disruptive Innovation Full Composite6.30M6.12%-2.11M
ARK Innovation ETF6.14M5.97%97.22K
Fidelity Growth Compy Commingled Pl S4.64M4.50%-
Fidelity Growth Company Fund3.46M3.36%-4.27K
State Street® SPDR® S&P® Biotech ETF3.32M3.21%7.61K
Vanguard Morn Total Stk Mkt Idx Investor3.27M3.18%185.33K
Vanguard Total Stock Mkt Idx Inv3.27M3.18%185.33K
Nikko AM ARK Disruptive Innovation A USD2.92M2.90%-98.23K
BB Biotech AG Ord2.89M2.84%-
iShares Russell 2000 ETF2.50M2.42%-44.45K

Recent Insider Transactions

DateNameRoleActivityValue
Jul 27, 2026Simon Amy Chief Medical OfficerSell$429.04K
Jun 30, 2026Simon Amy Chief Medical OfficerSell$12.95K
Jun 30, 2026Evans John M. CEOSell$66.20K
Jun 29, 2026Evans John M. CEOSell$471.53K
Jun 30, 2026Evans John M. CEOSell$791.48K

Insider Transactions Trends

DateBuySell
2033 Q2--
2024 Q4-2
2024 Q3-3
2024 Q2-7
2024 Q1-7

BEAM Ownership FAQ

Who Owns Beam Therapeutics?

Beam Therapeutics shareholders are primarily institutional investors at 25.87%, followed by 1.36% insiders and 72.77% retail investors. The average institutional ownership in Beam Therapeutics's industry, Biotech Stocks , is 35.43%, which Beam Therapeutics falls below.

Who owns the most shares of Beam Therapeutics?

Beam Therapeutics’s largest shareholders are Ark investment management (12.13M shares, 12.27%), Fmr (12.61M shares, 12.21%), and Farallon capital management (10.13M shares, 10.25%). Together, they hold 34.73% of Beam Therapeutics’s total shares outstanding.

Does Blackrock own Beam Therapeutics?

Yes, BlackRock owns 9.34% of Beam Therapeutics, totaling 7.63M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 178.87M$. In the last quarter, BlackRock increased its holdings by 928.75K shares, a 13.85% change.

Who is Beam Therapeutics’s biggest shareholder by percentage of total assets invested?

Mwg management is Beam Therapeutics’s biggest shareholder by percentage of total assets invested, with 67.66% of its assets in 2.27M Beam Therapeutics shares, valued at 55.02M$.

Who is the top mutual fund holder of Beam Therapeutics shares?

ARK Disruptive Innovation Full Composite is the top mutual fund holder of Beam Therapeutics shares, with 6.12% of its total shares outstanding invested in 6.3M Beam Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools